Dr. Christian Iorio-Morin, M.D. Ph.D.
Claim this profileCentre Hospitalier Universitaire de Sherbrooke
Studies Oral Mucosa Hematoma
Studies Chronic Subdural Hematoma
4 reported clinical trials
7 drugs studied
Affiliated Hospitals
Clinical Trials Christian Iorio-Morin, M.D. Ph.D. is currently running
Nerve Field Stimulation
for Trigeminal Neuralgia
This trial tests a treatment where small electrical devices are placed under the skin near facial nerves to reduce pain. It targets patients with facial pain who have already had surgery. The device sends tiny electrical pulses to block pain signals.
Recruiting0 awards Phase 1 & 2
Tranexamic Acid
for Subdural Hematoma
BACKGROUND Chronic subdural hematoma (CSDH) is one of the most frequent reasons for cranial neurosurgical consult. There is no widely accepted medical treatment for CSDH. This trial will investigate whether Tranexamic Acid (TXA) can increase the rate of CSDH resolution following conservative management, lower the number of required surgical procedures and decrease the rate of CSDH recurrence following surgical evacuation. TRACS is a double blind, randomized, parallel-design, placebo-controlled, phase IIB study designed to provide preliminary efficacy data as well as feasibility, safety and incidence data required to plan a larger definitive phase III trial. METHODS Consecutive patients presenting at the Centre Hospitalier Universitaire de Sherbrooke with a recent (\< 14 days) diagnosis of subdural hematoma with a chronic component will be screened for eligibility. Exclusion criteria include specific risk factors for thromboembolic disease, anticoagulant use or contraindication to TXA. A total of 130 patients will be randomized to receive either 750 mg of TXA daily or placebo until complete radiological resolution of the CSDH or for a maximum of 20 weeks. CSDH volume will be measured on serial CT scanning. Cognitive function tests, quality of life questionnaires as well as functional autonomy assessments will be performed at enrollment, 10 weeks follow-up and 3 months post-treatment follow-up. During the treatment period, patients will undergo standard CSDH management with surgery being performed at the discretion of the treating physician. If surgery is performed, the CSDH and its outer membrane will be sampled for in vitro analysis. The primary outcome is the rate of CSDH resolution at 20 weeks without intervening unplanned surgical procedure. Secondary outcomes include CSDH volume, incidence of surgical evacuation procedures, CSDH recurrence, cognitive functions, functional autonomy, quality of life, incidence of complications and length of hospital stay. Planned subgroup analyses will be performed for conservatively vs surgically-managed subjects and highly vs poorly vascularised CSDH. DISCUSSION CSDH is a frequent and morbid condition for which an effective medical treatment has yet to be discovered. The TRACS trial will be the first prospective study of TXA for CSDH.
Recruiting0 awards Phase 2 & 32 criteria
More about Christian Iorio-Morin, M.D. Ph.D.
Clinical Trial Related2 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Christian Iorio-Morin, M.D. Ph.D. has experience with
- Stereotactic RadioSurgery (SRS)
- Placebo
- Tranexamic Acid
- Paresthesia-free Peripheral Nerve Field Stimulation
- Sham Stimulation
- Levetiracetam
Breakdown of trials Christian Iorio-Morin, M.D. Ph.D. has run
Oral Mucosa Hematoma
Chronic Subdural Hematoma
Intracranial Aneurysms
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christian Iorio-Morin, M.D. Ph.D. specialize in?
Christian Iorio-Morin, M.D. Ph.D. focuses on Oral Mucosa Hematoma and Chronic Subdural Hematoma. In particular, much of their work with Oral Mucosa Hematoma has involved treating patients, or patients who are undergoing treatment.
Is Christian Iorio-Morin, M.D. Ph.D. currently recruiting for clinical trials?
Yes, Christian Iorio-Morin, M.D. Ph.D. is currently recruiting for 2 clinical trials in Sherbrooke Quebec. If you're interested in participating, you should apply.
Are there any treatments that Christian Iorio-Morin, M.D. Ph.D. has studied deeply?
Yes, Christian Iorio-Morin, M.D. Ph.D. has studied treatments such as Stereotactic RadioSurgery (SRS), Placebo, Tranexamic Acid.
What is the best way to schedule an appointment with Christian Iorio-Morin, M.D. Ph.D.?
Apply for one of the trials that Christian Iorio-Morin, M.D. Ph.D. is conducting.
What is the office address of Christian Iorio-Morin, M.D. Ph.D.?
The office of Christian Iorio-Morin, M.D. Ph.D. is located at: Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec J1H 5N4 Canada. This is the address for their practice at the Centre Hospitalier Universitaire de Sherbrooke.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.